Coya Therapeutics, Inc.
COYA
$4.48
-$0.07-1.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -93.66% | 11.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -93.66% | 11.10% | |||
| Cost of Revenue | -17.08% | 69.38% | |||
| Gross Profit | -266.58% | -251.45% | |||
| SG&A Expenses | 15.66% | 27.86% | |||
| Depreciation & Amortization | -58.82% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.09% | 49.92% | |||
| Operating Income | -79.23% | -122.09% | |||
| Income Before Tax | -26.32% | -169.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.25% | -169.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.25% | -169.80% | |||
| EBIT | -79.23% | -122.09% | |||
| EBITDA | -79.45% | -122.52% | |||
| EPS Basic | 6.66% | -169.78% | |||
| Normalized Basic EPS | -35.29% | -145.48% | |||
| EPS Diluted | -87.18% | -169.78% | |||
| Normalized Diluted EPS | -35.29% | -145.48% | |||
| Average Basic Shares Outstanding | 35.25% | 0.06% | |||
| Average Diluted Shares Outstanding | 35.25% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||